Tegoprazan
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Tegoprazan
Description:
Tegoprazan (CJ-12420), a potassium-competitive acid blocker, is a reversible, orally active and highly selective inhibitor of gastric H+/K+-ATPase. Tegoprazan inhibits gastric acid secretion and motility against porcine, canine and human H+/K+-ATPase with IC50 values ranging from 0.29-0.52 μM in vitro. Tegoprazan significantly improves colitis and enhances the intestinal epithelial barrier function in mice. Tegoprazan is promising for research of Inflammatory bowel, gastric acid-related, motilityimpaired diseases[1][2][3].Product Name Alternative:
CJ-12420; RQ-00000004UNSPSC:
12352005Hazard Statement:
H302, H315, H319, H335Target:
Na+/K+ ATPase; Potassium Channel; Proton PumpType:
Reference compoundRelated Pathways:
Membrane Transporter/Ion ChannelApplications:
Metabolism-protein/nucleotide metabolismField of Research:
Inflammation/ImmunologyAssay Protocol:
https://www.medchemexpress.com/Tegoprazan.htmlConcentration:
10mMPurity:
99.76Solubility:
DMSO : 100 mg/mL (ultrasonic)Smiles:
FC1=CC(F)=C2[C@@H](OC3=CC(C(N(C)C)=O)=CC4=C3N=C(C)N4)CCOC2=C1Molecular Formula:
C20H19F2N3O3Molecular Weight:
387.38Precautions:
H302, H315, H319, H335References & Citations:
[2]Son M, et al. Novel Potassium-Competitive Acid Blocker, Tegoprazan, Protects Against Colitis by Improving Gut Barrier Function[J]. Front Immunol. 2022 May 25;13:870817. |[3]Kim DK, et al. Effects of Tegoprazan, a Novel Potassium-Competitive Acid Blocker, on Rat Models of Gastric Acid-Related Disease[J]. J Pharmacol Exp Ther. 2019 Jun;369 (3) :318-327. |[1]Takahashi N, et al. Tegoprazan, a Novel Potassium-Competitive Acid Blocker to Control Gastric Acid Secretion and Motility. J Pharmacol Exp Ther. 2018 Feb;364 (2) :275-286.Shipping Conditions:
Room TemperatureStorage Conditions:
-20°C, 3 years; 4°C, 2 years (Powder)Scientific Category:
Reference compound1Clinical Information:
LaunchedCAS Number:
[942195-55-3]
